Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
A phase 1/2 trial of Tislelizumab in hepatocellular carcinoma and colorectal cancer, run by Indaptus Therapeutics, Inc, active and no longer recruiting.
Overview
Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05651022 by Indaptus Therapeutics, Inc, with 120 participants planned, started 2023-02-28 and due to reach its primary completion in 2027-06-30. Interventions recorded: Decoy20, Tislelizumab. Conditions listed: Solid Tumor, Adult, HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer), Pancreatic Adenocarcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Sol
Shares Tislelizumab, Hepatocellular carcinoma, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPhase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Adva
Shares Tislelizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- PersonJie Wang
Shares Tislelizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus
Shares Tislelizumab, Colorectal cancer.
- TrialAK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
Shares Tislelizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialComparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)
Shares Tislelizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
Shares Tislelizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Shares Tislelizumab, Colorectal cancer, Non-small-cell lung cancer.